Targeting the Epidermal Growth Factor Receptor in Solid Tumor Malignancies

No abstract is available for this paper.

• Publication year

  2012

• Venue

  BioDrugs

• Publication date

  2012-08-16

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2165/11599760-000000000-00000PMID 22385404
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Human Metabolism of Lapatinib, a Dual Kinase Inhibitor: Implications for Hepatotoxicity

  2012cited by this paper
• Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer

  2012cited by this paper
• Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.

  2012cited by this paper
• Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial.

  2011cited by this paper
• The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer

  2011cited by this paper
• Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.

  2011cited by this paper
• A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer.

  2011cited by this paper
• Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.

  2011cited by this paper
• Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy

  2011cited by this paper
• Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial.

  2011cited by this paper
• Bivalent binding by intermediate affinity of nimotuzumab: A contribution to explain antibody clinical profile

  2011cited by this paper
• A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143)

  2011cited by this paper
• Preclinical Pharmacokinetics and Safety of Sym004: A Synergistic Antibody Mixture Directed against Epidermal Growth Factor Receptor

  2011cited by this paper
• A phase I study of nimotuzumab in combination with radiotherapy in stages IIB-IV non-small cell lung cancer unsuitable for radical therapy: Korean results.

  2011cited by this paper
• Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.

  2011cited by this paper
• Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.

  2011cited by this paper
• Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.

  2011cited by this paper
• Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors.

  2011cited by this paper
• Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC)

  2011cited by this paper
• Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development

  2011cited by this paper
• Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial

  2011cited by this paper
• A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies

  2011cited by this paper
• Structural Evidence for Loose Linkage between Ligand Binding and Kinase Activation in the Epidermal Growth Factor Receptor

  2010cited by this paper
• Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.

  2010cited by this paper
• Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

  2010cited by this paper
• A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme.

  2010cited by this paper
• Necitumumab, a fully human IgG1 mAb directed against the EGFR for the potential treatment of cancer.

  2010cited by this paper
• Spatial control of EGF receptor activation by reversible dimerization on living cells

  2010cited by this paper
• Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy.

  2010cited by this paper
• Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.

  2010cited by this paper
• Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial.

  2010influential reference
• Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.

  2010influential reference
• A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies

  2010cited by this paper
• Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancer.

  2010cited by this paper
• The emerging role of nimotuzumab in the treatment of non-small cell lung cancer

  2010cited by this paper
• Exciting New Advances in Neuro‐Oncology: The Avenue to a Cure for Malignant Glioma

  2010cited by this paper
• Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.

  2010cited by this paper
• Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.

  2010cited by this paper
• Phase II, Randomized Trial to Compare Anastrozole Combined with Gefitinib or Placebo in Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer

  2010cited by this paper
• Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance.

  2010cited by this paper
• Could Autoimmunity Be Induced by Vaccination?

  2010cited by this paper
• Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].

  2009cited by this paper
• A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors

  2009cited by this paper
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

  2009cited by this paper
• A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.

  2009cited by this paper
• The EGFR network in bone biology and pathology.

  2009cited by this paper
• Humanized immunotoxins: A new generation of immunotoxins for targeted cancer therapy

  2009cited by this paper
• Targeting cancer with small molecule kinase inhibitors

  2009cited by this paper
• Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects.

  2009cited by this paper
• Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

  2009cited by this paper
• Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.

  2009cited by this paper
• A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer

  2009cited by this paper
• Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.

  2009cited by this paper
• The cancer vaccine roller coaster

  2009cited by this paper
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

  2009cited by this paper
• Epidermal growth factor receptor signaling in liver cell proliferation and apoptosis

  2009cited by this paper
• Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients.

  2008cited by this paper
• Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging.

  2008cited by this paper
• An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy.

  2008cited by this paper
• Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.

  2008cited by this paper
• Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

  2008cited by this paper
• Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188-Re in adult recurrent high-grade glioma

  2008cited by this paper
• Postoperative Adjuvant Dendritic Cell–Based Immunotherapy in Patients with Relapsed Glioblastoma Multiforme

  2008cited by this paper
• EGFR family: Structure physiology signalling and therapeutic targets†

  2008influential reference
• Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors.

  2008cited by this paper
• Toxicology Study of Repeat Intracerebral Administration of a Measles Virus Derivative Producing Carcinoembryonic Antigen in Rhesus Macaques in Support of a Phase I/II Clinical Trial for Patients with Recurrent Gliomas

  2008cited by this paper
• Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines.

  2008cited by this paper
• Structure-based view of epidermal growth factor receptor regulation.

  2008cited by this paper
• Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization.

  2008cited by this paper
• Platinum-based chemotherapy plus cetuximab in head and neck cancer.

  2008cited by this paper
• Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8.

  2008cited by this paper
• Association of epidermal growth factor receptor (EGFR) gene mutations with EGFR amplification in advanced non‐small cell lung cancer

  2008cited by this paper
• The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility

  2008cited by this paper
• Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.

  2007cited by this paper
• Biological Activity In Vitro of Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies with Different Affinities

  2007influential reference
• Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial.

  2007cited by this paper
• Mechanisms for oncogenic activation of the epidermal growth factor receptor.

  2007cited by this paper
• Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

  2007cited by this paper
• Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer.

  2007cited by this paper
• A phase II clinical trial of ZD1839 (Iressa™) in combination with docetaxel as first-line treatment in patients with advanced breast cancer

  2007cited by this paper
• Antibody-Dependent Cellular Cytotoxicity Mediated by Cetuximab against Lung Cancer Cell Lines

  2007influential reference
• Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

  2007cited by this paper
• Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas.

  2007cited by this paper
• Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action.

  2006cited by this paper
• Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity.

  2006cited by this paper
• Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting

  2006cited by this paper
• An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor.

  2006cited by this paper
• Effect of the anti-receptor ligand-blocking 225 monoclonal antibody on EGF receptor endocytosis and sorting.

  2006cited by this paper
• EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells

  2006cited by this paper
• Dermatologic side effects associated with the epidermal growth factor receptor inhibitors.

  2006cited by this paper
• Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

  2006cited by this paper
• Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells.

  2006cited by this paper
• Autoimmunity during lymphopenia: a two-hit model.

  2006cited by this paper
• Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.

  2006cited by this paper
• Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer

  2006cited by this paper
• ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors

  2005influential reference
• Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer.

  2005cited by this paper
• Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).

  2005cited by this paper
• Prognostic Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients

  2005cited by this paper
• Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor Microenvironment

  2005cited by this paper

• Immunohistochemical expression of epidermal growth factor receptor: prognostic value in HER2 positive breast cancer

  2025cites this paper
• Viral therapy for targeted drug delivery to cancers: Recent advances, clinical and regulatory perspectives

  2024cites this paper
• Surface functionalized nanomaterial systems for targeted therapy of endocrine related tumors: a review of recent advancements

  2024cites this paper
• Recent updates on thienopyrimidine derivatives as anticancer agents

  2023cites this paper
• Hybrid exosomes, exosome-like nanovesicles and engineered exosomes for therapeutic applications.

  2022cites this paper
• Expedition into Exosome Biology: A Perspective of Progress from Discovery to Therapeutic Development

  2021cites this paper
• Coexistence of BRAFV600E mutation and EGFR overexpression is highly associated with adverse clinicopathological features of papillary thyroid carcinoma

  2020cites this paper
• Designer Exosomes: A New Platform for Biotechnology Therapeutics

  2020cites this paper
• Multidirectional Strategies for Targeted Delivery of Oncolytic Viruses by Tumor Infiltrating Immune Cells.

  2020cites this paper
• EGFR and CXCR1 expression in thyroid carcinoma in Qassim Region-Saudi Arabia: Correlation with clinicopathological parameters.

  2019cites this paper
• Overexpression of epidermal growth factor receptor and its downstream effector, focal adhesion kinase, correlates with papillary thyroid carcinoma progression

  2018cites this paper
• Aptamer-Conjugated Extracellular Nanovesicles for Targeted Drug Delivery.

  2018cites this paper
• The Immunogenicity and Anti-Tumor Efficacy of a Rationally Designed EGFR Vaccine

  2018cites this paper
• Discovery of novel substituted benzo-anellated 4-benzylamino pyrrolopyrimidines as dual EGFR and VEGFR2 inhibitors.

  2017cites this paper
• Targeting neoantigens to augment antitumour immunity

  2017cites this paper
• Cytokines for the induction of antitumor effectors: The paradigm of Cytokine-Induced Killer (CIK) cells.

  2017cites this paper
• Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and IGF-1R

  2017cites this paper
• Development and Validation of a Method for Quantifying HER1 Extracellular Domain in Culture Supernatant by RP-HPLC

  2016cites this paper
• Growth factor pathways in hypertrophic scars: Molecular pathogenesis and therapeutic implications.

  2016cites this paper
• Understanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model

  2016cites this paper
• Discovery of dually acting small-molecule inhibitors of cancer-resistance relevant receptor tyrosine kinases EGFR and IGF-1R

  2016cites this paper
• Preclinical PET imaging of EGFR levels: pairing a targeting with a non-targeting Sel-tagged Affibody-based tracer to estimate the specific uptake

  2016cites this paper
• Evaluation of 18F-labeled icotinib derivatives as potential PET agents for tumor imaging

  2016cites this paper
• Modification of cytokine-induced killer cells with chimeric antigen receptors (CARs) enhances antitumor immunity to epidermal growth factor receptor (EGFR)-positive malignancies

  2015cites this paper
• Cancer Neoantigens: A Promising Source of Immunogens for Cancer Immunotherapy

  2015cites this paper
• Assessment of the impact of manufacturing changes on the physicochemical properties and biological activity of Her1-ECD vaccine during product development.

  2015influential citation
• Biologically driven synthesis of pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors: an old scaffold as a new tool for medicinal chemistry and chemical biology studies.

  2014cites this paper
• Three-Dimensional Lung Tumor Microenvironment Modulates Therapeutic Compound Responsiveness In Vitro – Implication for Drug Development

  2014cites this paper
• High expression of GPER1, EGFR and CXCR1 is associated with lymph node metastasis in papillary thyroid carcinoma.

  2014cites this paper
• EGFR signaling patterns are regulated by its different ligands

  2014cites this paper
• Structure-activity study leading to identification of a highly active thienopyrimidine based EGFR inhibitor.

  2014cites this paper
• Identification of new 4-N-substituted 6-aryl-7H-pyrrolo[2,3-d]pyrimidine-4-amines as highly potent EGFR-TK inhibitors with Src-family activity.

  2014cites this paper
• Topics in cancer genomics

  2014cites this paper
• A comprehensive overview of exosomes as drug delivery vehicles - endogenous nanocarriers for targeted cancer therapy.

  2014cites this paper
• Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia.

  2014cites this paper
• High expression of GPER 1 , EGFR and CXCR 1 is associated with lymph node metastasis in papillary thyroid carcinoma

  2014cites this paper
• Cellular changes, molecular pathways and the immune system following photodynamic treatment.

  2014cites this paper
• Exploring pyrimidine-substituted curcumin analogues: design, synthesis and effects on EGFR signaling.

  2013cites this paper
• A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity

  2013cites this paper